2018 Press Releases

Aptinyx logo

Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
December 3, 2018

Kitcheck logo

Kit Check Announces “Works with Kit Check” Certification Program for Hospital Pharmacy Vendors
December 3, 2018

Principia

PRINCIPIA BIOPHARMA REPORTS POSITIVE PRN1008 PHASE 2 TOP-LINE RESULTS AND INITIATES PHASE 3 PEMPHIGUS PROGRAM
November 29, 2018

Edge Therapeutics

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company
November 26, 2018

Aptinyx logo

Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans
November 12, 2018

Harpoon Therapeutics logo

HARPOON THERAPEUTICS ANNOUNCES CLOSING OF $70M SERIES C FINANCING
November 11, 2018

Harpoon Therapeutics logo

HARPOON THERAPEUTICS UNVEILS PROTRITAC PLATFORM: A NOVEL, PROTEASE-ACTIVATED T CELL ENGAGER PLATFORM DESIGNED TO ACCESS A BROAD LANDSCAPE OF SOLID TUMOR TARGETS
November 9, 2018

Aptinyx logo

Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy
November 1, 2018

Principia

PRINCIPIA BIOPHARMA APPOINTS DOLCA THOMAS, M.D. AS CHIEF MEDICAL OFFICER
October 24, 2018

Principia

PRINCIPIA BIOPHARMA ANNOUNCES PRN1008 RECEIVES ORPHAN-DRUG DESIGNATION FROM FDA FOR TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA
October 19, 2018

CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases
October 17, 2018

Principia

PRINCIPIA ACHIEVES $10 MILLION IN ADDITIONAL MILESTONES RELATED TO DEVELOPMENT OF PRN2246/SAR442168
October 16, 2018

Harpoon Therapeutics logo

Harpoon Therapeutics announces appointment of Natalie R. Sacks, M.D., as Chief Medical Officer
October 3, 2018

Kitcheck logo

Kit Check Closes the Diversion Gap with Launch of Bluesight IRIS and Reveals Which Hospital Employees Exhibit Behaviors Consistent with Controlled Substance Theft
October 1, 2018

Arvinas logo

Arvinas announces pricing of initial public offering
September 26, 2018

Principia

Principia Biopharma announces closing of initial public offering and full exercise of underwriters’ option to purchase additional shares
September 18, 2018

Harpoon Therapeutics logo

Harpoon Therapeutics announces appointments to Board of Directors and Management Team
September 18, 2018

Interum logo

Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
September 18, 2018

Aptinyx logo

UNUM Therapeutics announces abstract accepted for presentation at the fourth CIMT-EATI-AACR International Cancer Immunotherapy Conference
September 17, 2018

Unum logo

Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain
September 14, 2018

Interum logo

Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
August 9, 2018

Rallybio

Rallybio Further Expands Drug Acquisition and Development Capabilities
August 7, 2018

Harpoon Therapeutics logo

Harpoon Therapeutics treats first patient with HPN424 in phase I clinical trial of metastatic castration-resistant prostate cancer (mCRPC) patients.
August 6, 2018

Aptinyx logo

Aptinyx Initiates Phase 1 Study of NYX-458
August 2, 2018

ReViral

ReViral announces Series B investment
August 1, 2018

Neuronetics Logo

Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Pricing of Initial Public Offering
June 28, 2018

Truveris logo

Truveris Expands Audit Capabilities with Launch of TruAudit
June 12, 2018

Deciphera logo

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
June 11, 2018

Deciphera logo

Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618. as Chief Technical Officer
June 2, 2018

Deciphera logo

Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer
May 29, 2018

NeuroStar® Advanced Therapy Reaches Monumental Milestone of 1.7 Million Treatments in the US
May 24, 2018

Neurana Pharmaceuticals

Neurana Pharmaceuticals Announces Completion of $60 Million Series A Financing
May 7, 2018

Neuronetics Logo

NeuroStar® Advanced Therapy Reaches Monumental Milestone of 1.7 Million Treatments in the US
May 5, 2018

Rallybio

Rallybio Completes $37.0M Series A Financing
April 24, 2018

Deciphera logo

Preclinical Data Demonstrate That Deciphera Pharmaceuticals’ DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents
April 17, 2018

Harpoon Therapeutics logo

Harpoon Therapeutics Launches Immuno-Oncology Pipeline with Compelling Data from Lead Programs at the 2018 American Association for Cancer Research (AACR) Annual Meeting Financing to Advance Protein Degradation Platform
April 16, 2018

Arvinas logo

Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
April 4, 2018

Aptinyx logo

Save

Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
March 15, 2018

Truveris logo

Truveris Appoints Sally Welborn, former head of Walmart Global Benefits to Board of Directors
March 20, 2018

Kyruus logo

Partners HealthCare Expands Use of Kyruus Technology Across Its Network to Enhance Patient Access
March 20, 2018

TigerConnect

TigerConnect Teams with QGen
March 7, 2018

TigerConnect

TigerText Renames As TigerConnect to Welcome a New Era of Clinical Communication
March 6, 2018

Kyruus logo

Kyruus Announces Collaboration with IBM to Leverage IBM Watson Virtual Agent with Kyruus ProviderMatch™ to Enable AI-Assisted Patient-Provider Matching and Scheduling
March 5, 2018

Iterum Announces the appointment of Jeff Schaffnit as Chief Commercial Officer
February 20, 2018

Arvinas logo

Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC® ARV-110 at ASCO 2018 Genitourinary Cancers Symposium
February 9, 2018

Kyruus logo

Kyruus Reports Record-Breaking Success in 2017 with Almost 400 Hospitals Across the U.S. Now on the ProviderMatch Platform
January 30, 2018

Kyruus logo

Kyruus Joins the Epic App Orchard with Direct Scheduling Solution
January 9, 2018

Arvinas logo

Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug Candidates
January 4, 2018

Deciphera logo

Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)
January 4, 2018